Press Room

Press Release / Jul 21, 2010

Hovione scientists bring PAT and inhalation expertise to USP

Loures, Portugal, July 21, 2010. Hovione is announcing the nomination of two of its scientists to the United States Pharmacopeia (USP), for the period 2010-2015. Jason Suggett, PhD has been named to the General Chapters – Dosage Forms Expert Committee and Nuno Matos is joining the Chemical Analysis Expert Committee.

Jason Suggett joins as an expert in the field of inhalation products and will contribute his knowledge in the area of new testing procedures for inhalation products. Nuno Matos is an expert in the field of process analytical technology (PAT), near-infrared spectroscopy and chemometrics.

Peter Villax, Vice-President said “Hovione has been active in the standard setting process for three decades now. We are delighted that two of our scientists are joining USP committees, and hope that their work brings a significant contribution, particularly in the areas of PAT and inhalation.”

The USP is a non-governmental, official public standards-setting authority responsible for overseeing standards for prescription medicines and other healthcare products manufactured or sold in the United States. USP's activities have a significant impact on promoting quality and protecting the public health worldwide.

About Hovione

Hovione is an international company with 51 years’ experience in Active Pharmaceutical Ingredient development and compliant manufacture, from molecule to unit dose. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on serving the most demanding customers in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
 

For further information about Hovione, please visit the Hovione site at www.hovione.com or contact Corporate Communications (Isabel Pina, + 351 21 982 9362, e-mail: hello@hovione.com)

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024